Method for Determining Rcc Subtypes

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a molecular method for objectively identifying the relative proportions of the three main subtypes of renal cell carcinoma (RCC)—papillary RCC (pRCC), clear cell RCC (ccRCC), and chromophobe RCC (chRCC)—in a patient’s biological sample by measuring the expression of specific signature genes for each subtype. By applying advanced signal separation analysis (such as deconvolution or machine learning) to these gene expression patterns, clinicians can accurately classify the tumor composition and assign patients to prognostic risk groups (“good,” “intermediate,” or “poor”), thereby improving diagnosis and treatment planning over traditional manual pathology methods.

Use CasesContent extracted from patent full text and abstract with AI.

• Clinical pathology laboratories for molecular subtype classification of RCC samples from biopsies or surgical specimens.
• Provision of objective diagnostic support for oncologists in renal cancer management.
• Risk stratification of RCC patients to personalize post-operative monitoring and adjuvant therapy decisions.
• Development and commercialization of diagnostic microarrays or molecular panels targeting RCC signature genes for hospital or central laboratories.
• Retrospective or real-time research studies analyzing RCC subtype distributions and associated survival outcomes.
• Optimizing patient selection for clinical trials based on objective subtype and risk assignment.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides objective, quantitative, and reproducible classification of RCC subtypes, reducing subjectivity and error associated with manual pathology.
• Enables more accurate prognosis and risk group allocation, directly associated with patient survival outcomes.
• Facilitates tailored treatment decisions and follow-up protocols based on precise tumor subtype composition and risk.
• Can utilize readily available molecular biology techniques (RNA-Seq, PCR, microarrays, antibodies), making implementation feasible in many clinical settings.
• Applicable even to histologically ambiguous or heterogeneous RCC tumors that combine features of multiple subtypes.
• No need for statistically validated reference samples, allowing standalone classification from patient data.
• Potentially automatable, speeding up workflow and reporting to the treating clinician.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a method for determining in a subject's biological sample the relative proportions of papillary renal cell carcinoma (pRCC), clear cell renal cell carcinoma (ccRCC), and chromophobe renal cell carcinoma (chRCC), an array comprising capture molecules capable of specifically binding to RCC signature genes or coding sequences thereof or products encoded thereby, and the use of RCC signature genes for classifying a subject into a renal cell carcinoma (RCC) risk group and/or for determining in a subject's biological sample the relative proportions of pRCC, ccRCC, and chRCC.